Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
IT0004147952
Fri, 13.12.2024
Newron Pharmaceuticals S.p.A.
Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories
Newron will receive up to a maximum of €117 million from an upfront payment, development milestones and commercialization milestones, and up to double-digit tiered royalties on net sales
Evenamide is a unique modul [ … ]
Thu, 19.09.2024
Newron Pharmaceuticals S.p.A.
Newron presents H1 2024 results and provides business update
Milan, Italy, September 19, 2024, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial [ … ]
Thu, 19.09.2024
Newron Pharmaceuticals S.p.A.
Newron presents H1 2024 results and provides business update
Milan, Italy, September 19, 2024, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial [ … ]
Tue, 25.06.2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City
Clinical results and new findings of mechanism of action indicate evenamide would be uniquely effective in patients with treatment resistant schizophrenia
Leading schizophrenia experts predict earlier use of evenamide would benefit patients with inadequate response
Evena [ … ]
Tue, 18.06.2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
Three of the world’s leading key opinion leaders (KOL) in neuroscience and schizophrenia to review and present findings on Newron’s evenamide program for treatment-resistant schizophrenia
The company will host a Live-Webcast of the event, beginning at 9:00 AM EDT (2 [ … ]
Wed, 05.06.2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City
New hope emerges for treatment-resistant schizophrenia: leading KOLs to reveal insights into the neurobiology of treatment for both poorly responding and treatment-resistant patients
Company to lay out the roadmap for US and EU registration for evenamide
Milan [ … ]
Mon, 13.05.2024
Newron Pharmaceuticals S.p.A.
Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
Further study analysis reveals significant multi-domain benefits in PANSS and Clinical Global Impression of Change (CGI-C) ratings
Benefit on efficacy measures increased over time, suggesting larger [ … ]
Tue, 30.04.2024
Newron Pharmaceuticals S.p.A.
Newron announces positive top-line results
from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified
Glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizoph [ … ]
Mon, 08.04.2024
Newron Pharmaceuticals S.p.A.
Data from Newron’s study 014/015 and an
evenamide clinical development outlook presented at
the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) for up to one year
Presentatio [ … ]
Tue, 19.03.2024
Newron Pharmaceuticals S.p.A.
Newron presents 2023 financial results and provides 2024 outlook
Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financ [ … ]